USA –US-based scientific equipment and software supply company Thermo Fisher Scientific Inc. has introduced new Gibco CTS Xenon Electroporation System, which allows for large-scale cell therapy development and clinical manufacturing.
The new electroporation system allows for gene modifications without the use of conventional viral vectors.
Developers will have complete control over optimizing various difficult-to-transfect cell types and payloads when using the Gibco CTS Xenon Electroporation System cell therapy.
The device, which has programmable, flexible electroporation conditions, can be used as a standalone technology or as part of an automated cell therapy manufacturing workflow with the Gibco CTS Rotea Counterflow Centrifugation System.
Thermo Fisher Scientific biosciences president Amy Butler said: “We launched the CTS Rotea System in 2020 as part of our strategy to deliver fit-for-purpose cell therapy solutions that can easily scale from development to commercialization.
“Adding the CTS Xenon Electroporation System to our end-to-end workflow will help customers overcome manufacturing challenges that hinder production, enabling them to bring life-saving therapies to patients faster.”
In a sterile system, the Xenon Electroporation System provides transfection performance in volumes of up to 2.5e9 cells in 25 mL. This allows for rapid non-viral transfection in clinical manufacturing applications.
Furthermore, the CTS solution achieves 90% gene knockout transfection and up to 80% cell viability, allowing scaling from the small-volume Neon Transfection System without the need to re-optimize electroporation parameters.
Thermo Fisher’s CTS product line is designed to address the manufacturing needs of cell therapy developers by working across the total process, from cell isolation/activation to cell engineering and expansion.
The Xenon Electroporation System is a Cell Therapy Systems (CTS) solution that is designed to easily transition from the bench to the clinic.
Thermo Fisher recently launched two new reverse transcription loop-mediated isothermal amplification-based solutions for viral pathogen surveillance, including SARS-CoV-2.
Meanwhile, Thermo Fisher Scientific is set to invest US$97 million in three new bioanalytical laboratory locations in Virginia’s Greater Richmond region, adding nearly 150,000 square feet to its existing operations in the area.
The existing laboratory services operation there spans more than 300,000 square feet, making it one of the world’s largest of its kind, and it employs over 1200 professionals, including PhD-level scientists, analytical laboratory staff, and other scientific professionals.
In December 2021, Thermo Fisher acquired the laboratories with the purchase of PPD, Inc., a provider of clinical research services to the biopharmaceutical industry.
Longer term, the company intends to continue to invest in and connect the combined company’s capabilities.
The bulk of the expansion will occur in immunochemistry and chromatography functions, as well as subsequent enhancements in biomarker and vaccine sciences.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE